Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan G Howlett

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
The Canadian Journal of Cardiology|February 14, 2009
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trialsJonathan G Howlett, Robert S McKelvie, J Malcolm O Arnold, et al.
The Canadian Journal of Cardiology|January 23, 2008
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesJ Malcom, O Arnold, Jonathan G Howlett, et al.
The Canadian Journal of Cardiology|February 2, 2006
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and managementJ Malcolm O Arnold, Peter Liu, Catherine Demers, et al.
The Canadian Journal of Cardiology|January 25, 2007
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkersJ Malcom O Arnold, Jonathan G Howlett, Paul Dorian, et al.
JACC. Heart Failure|September 16, 2019
CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH TrialJonathan G Howlett, Amanda Stebbins, Mark C Petrie, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
The American Journal of Cardiology|April 26, 2016
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)Marco Metra, Robert J Mentz, Adrian F Hernandez, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
The Canadian Journal of Cardiology|February 14, 2009
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trialsJonathan G Howlett, Robert S McKelvie, J Malcolm O Arnold, et al.
The Canadian Journal of Cardiology|January 23, 2008
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesJ Malcom, O Arnold, Jonathan G Howlett, et al.
The Canadian Journal of Cardiology|February 2, 2006
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and managementJ Malcolm O Arnold, Peter Liu, Catherine Demers, et al.
The Canadian Journal of Cardiology|January 25, 2007
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkersJ Malcom O Arnold, Jonathan G Howlett, Paul Dorian, et al.
JACC. Heart Failure|September 16, 2019
CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH TrialJonathan G Howlett, Amanda Stebbins, Mark C Petrie, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Heart Journal|December 22, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetesWilliam T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, et al.
The American Journal of Cardiology|April 26, 2016
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)Marco Metra, Robert J Mentz, Adrian F Hernandez, et al.
European Heart Journal|March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapyKieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
Pageof 13